An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer
An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer
批准号:
9185273
负责人:
Dayanidhi Raman
金额:
$16.48万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-12-01 至 2018-11-30
关键词:
AMD3100AgarAmino AcidsAnchorage-Independent GrowthAntibodiesAreaBindingBiochemicalBiologicalBiological AssayBone ResorptionBreast Cancer CellBreast Cancer cell lineBreast cancer metastasisCXC ChemokinesCXCL12 geneCXCR3 geneCXCR4 ReceptorsCXCR4 geneCancer EtiologyCancer PatientCell NucleusCell membraneCellsCessation of lifeChemotaxisComplexComputer softwareConfocal MicroscopyCytoplasmDominant-Negative MutationE-CadherinEmbryonic DevelopmentEpigenetic ProcessEpithelialEstrogen ReceptorsEventFructose-1,6-BisphosphataseGoalsGrowthHistone H3HistonesIL8RA geneIL8RB geneIn SituIn VitroIndividualKnock-outLabelLigationLightLinkLysineLytic Metastatic LesionMDA MB 231MapsMediatingMesenchymalMetastatic breast cancerMolecularMutagenesisMutationNeoplasm MetastasisNuclearNucleosomesOsteolyticParnatePeptidesPhenotypePlayPrimary NeoplasmProgram DevelopmentProteinsProteomicsRecombinantsRecruitment ActivityResearchResistanceRoleSUM-159 Breast Cancer Cell LineShapesSiteSite-Directed MutagenesisSnailsSurvival RateTestingTransforming Growth FactorsTumor InitiatorsWomanbonecancer cellcell motilitychemokinechemokine receptorchemotherapeutic agentchromatin immunoprecipitationdemethylationepigenomehistone methylationinhibitor/antagonistknock-downmalignant breast neoplasmmatrigelmigrationmortalitymutantnew therapeutic targetnovelparathyroid hormone-related proteinpromoterpublic health relevanceslugsmall molecule inhibitorstemnesstranscription factortriple-negative invasive breast carcinomatumor microenvironmenttumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of the proposed research is to investigate the role of CXCL12-driven nuclear LASP1 in modulation of epigenetic events in breast cancer. LASP-1 mediates cell migration, proliferation and survival in several breast cancer cell lines. Silencing of LASP-1 inhibits proliferation and migration by 45%. Previously, LASP-1 was demonstrated to directly interact with CXC chemokine receptors, CXCR1, CXCR2, CXCR3 and CXCR4 that play a key role in the tumor microenvironment facilitating breast cancer progression and metastasis. In particular, LASP-1 augmented CXCR2-mediated cell migration. Epigenetic alterations in breast cancer cells convert them into aggressive and metastatic phenotype. In this study, through proteomics, UHRF1 was discovered as a novel LASP-1 associating protein. Subsequently, DNMT1, G9a and Snail1 were also observed to associate with LASP-1. In particular, Snail1 was found to directly bind to LASP-1. The biological implication of this direct interaction is unclear. First, I propose to map the interaction sites between LASP-1 and Snail1 by mutational and biochemical approaches. I further propose to study the LASP1-Snail1 complex for its ability to modulate the E-cadherin promoter. Additionally, as Snail1 directly binds
to lysine demethyalse1 (LSD1), LSD1 will be analyzed whether it associates with LASP1-Snail1 complex by biochemical studies. Functionally, I propose to perform a chromatin immunoprecipitation (ChIP) analysis for LASP-1, LSD1, and K4/9 methylation of histone H3 to see if LASP-1/LSD1 co-localize to regions with demethylated histones upon stimulation with CXCL12. Alternatively, recombinant LASP-1 will be mixed with purified LSD-1 and see if LASP-1 enhances in vitro demethylation activity on labeled histone H3 or nucleosome substrates. Additionally, non-silenced and LASP1-knock down basal- like breast cancer cells will be tested for their ability to facilitate bone resorption in a dentine disk assay. LASP1-Snail1 axis would become a novel drug target for small molecule inhibitors with the aim of prolonging the survival rate especially in triple-negative breast cancer patients. Novel inhibitors might be even more useful in cases of breast cancer that are resistant to current chemotherapeutic agents.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3389/fonc.2018.00391
发表时间:
2018
期刊:
Frontiers in oncology
影响因子:
4.7
作者:
[Butt E, Raman D]
通讯作者:
Raman D
DOI:
10.3390/cancers12092455
发表时间:
2020-08-29
期刊:
Cancers
影响因子:
5.2
作者:
[Tilley AMC, Howard CM, Sridharan S, Subramaniyan B, Bearss NR, Alkhalili S, Raman D]
通讯作者:
Raman D
DOI:
10.3390/cancers12092372
发表时间:
2020-08-21
期刊:
Cancers
影响因子:
5.2
作者:
[Subramaniyan B, Sridharan S, M Howard C, M C Tilley A, Basuroy T, de la Serna I, Butt E, Raman D]
通讯作者:
Raman D
DOI:
10.1002/cnr2.1299
发表时间:
2022-12
期刊:
CANCER REPORTS
影响因子:
1.7
作者:
[Raman, Dayanidhi, Tiwari, Amit K.]
通讯作者:
Tiwari, Amit K.
DOI:
10.3390/cancers13081954
发表时间:
2021-04-18
期刊:
Cancers
影响因子:
5.2
作者:
[Tukaramrao DB, Malla S, Saraiya S, Hanely RA, Ray A, Kumari S, Raman D, Tiwari AK]
通讯作者:
Tiwari AK
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
-
批准号:10544331
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2022
-
负责人:Dayanidhi Raman
-
依托单位:
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
-
批准号:10366263
-
项目类别:
-
资助金额:$40.87万
-
财政年份:2022
-
负责人:Dayanidhi Raman
-
依托单位:
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
-
批准号:10680365
-
项目类别:
-
资助金额:$40.06万
-
财政年份:2022
-
负责人:Dayanidhi Raman
-
依托单位:
Targeting of eIF4A along with immunotherapy to overcome chemoresistance
-
批准号:10357016
-
项目类别:
-
资助金额:$21.67万
-
财政年份:2022
-
负责人:Dayanidhi Raman
-
依托单位:
An epigenetic link from CXCL12-CXCR4 axis through nuclear LASP-1 in breast cancer
-
批准号:9204937
-
项目类别:
-
资助金额:$19.77万
-
财政年份:2015
-
负责人:Dayanidhi Raman
-
依托单位:
国内基金
海外基金
Cd(II)在NH2-Agar/PSS双网络水凝胶上的吸附行为及资源化工艺研究
-
批准号:51708204
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2017
-
负责人:周贵寅
-
依托单位: